Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Xilio Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +4 vs. Q1 2026
- Shares held
- 3.41M
- +792.0K (+30.3%) vs. Q1 2026
- Total value
- $32.6M
- +$10.6M (+48.4%) vs. Q1 2026
- New holders
- 11
- 4 more added
- Sold out
- 7
- 4 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $14.0M |
| Q4 2023 | 34 | $9.11M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $57.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | $6.36M | 0.38% | 00.0% | Unchanged |
| Gilead Sciences, Inc. | 650,389 | $6.23M | 0.38% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 592,300 | $5.67M | 0.11% | +592,300 | New |
| Frazier Life Sciences Management, L.P. | 422,505 | $4.05M | 0.09% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 225,994 | $2.17M | 1.65% | +161,832+252.2% | Added |
| Vanguard Capital Management LLC | 178,517 | $1.71M | 0.00% | +54,857+44.4% | Added |
| Sio Capital Management, LLC | 152,464 | $1.46M | 0.25% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 111,541 | $1.07M | 0.00% | +111,541 | New |
| Merck & Co., Inc. | 105,982 | $1.02M | 0.19% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 64,153 | $614.6K | 0.00% | +14,587+29.4% | Added |
| Morgan Stanley | 56,954 | $545.6K | 0.00% | −539−0.9% | Reduced |
| Geode Capital Management, LLC | 39,055 | $374.2K | 0.00% | +1,858+5.0% | Added |
| Citadel Advisors LLC | 25,950 | $248.6K | 0.00% | +25,950 | New |
| Vanguard Fiduciary Trust Co | 22,594 | $216.5K | 0.00% | −5,881−20.7% | Reduced |
| Bridgeway Capital Management, LLC | 17,544 | $168.1K | 0.00% | +17,544 | New |
| Two Sigma Investments, LP | 14,544 | $139.3K | 0.00% | +14,544 | New |
| Velan Capital Investment Management LP | 14,285 | $136.8K | 0.08% | 00.0% | Unchanged |
| Gsa Capital Partners LLP | 13,590 | $130.0K | 0.01% | −3,356−19.8% | Reduced |
| State Street Corp | 13,311 | $127.5K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 11,600 | $111.1K | 0.01% | +11,600 | New |
| BlackRock, Inc. | 8,757 | $83.9K | 0.00% | +8,757 | New |
| Steward Partners Investment Advisory, LLC | 714 | $6.84K | 0.00% | +714 | New |
| Security National Bank of Sioux City Iowa | 321 | $3.08K | 0.00% | +321 | New |
| Barclays PLC | 115 | $1.10K | 0.00% | +115 | New |
| Key Financial Inc | 59 | $565 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 29 | $262 | 0.00% | +29 | New |
| UBS Group AG | 14 | $134 | 0.00% | −4,024−99.7% | Reduced |
| Caligan Partners LP | 0 | $0 | 0.00% | −112,128−100.0% | Sold out |
| AJU IB Investment Co., Ltd. | 0 | $0 | 0.00% | −47,695−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −36,558−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −13,800−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −240−100.0% | Sold out |
| Vanguard Global Advisers, LLC | 0 | $0 | 0.00% | −210−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |